Peek behind the paper: A compact and simple method of achieving differential transgene expression by exploiting translational readthrough

James Sillibourne (below) is Director of Synthetic Genomics at Autolus Therapeutics (London, UK), a biotech company focussing on developing chimeric antigen-receptor T-cell (CAR-T) therapies for the treatment of hematological and solid cancers. Sillibourne’s group uses genome editing techniques to engineer cell lines and edit primary T cells. Here, Sillibourne discusses his group’s paper that was recently published in BioTechniques, reporting a simple method to achieve differential transgene expression. This method could be used to avoid toxicity issues as downregulating transgene expression achieves ultra-low antigen levels, thereby controlling the expression of highly potent molecules. Please provide a short summary of your...